Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stephen Harvey Zinner, M.D.


This page shows the publications Stephen Zinner has written about Piperacillin.
Connection Strength

  1. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003 Aug 01; 37(3):382-9.
    View in: PubMed
    Score: 0.067
  2. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother. 1994 Oct; 38(10):2351-6.
    View in: PubMed
    Score: 0.037
  3. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother. 1991 May; 35(5):873-8.
    View in: PubMed
    Score: 0.029
  4. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods. J Antimicrob Chemother. 1986 Mar; 17 Suppl A:1-5.
    View in: PubMed
    Score: 0.020
  5. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 1995 Feb; 39(2):445-52.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.